|
|
 |
|
 |
|
|
|
|
Title:
|
Paclitaxel-Associated Acute Pain Syndrome Natural History Study - IRB# 09-032A
|
|
Treatments:
|
-- none --
|
|
Disease Site:
|
Cancer control
|
|
Disease SubSite:
|
Paclitaxel-Associated Acute Pain Syndrome
|
|
Drug Provided:
|
-- none --
|
|
Comments:
|
Arm B of this study is closed to accrual for the general patient population, but will remain open to minority accrual only. Arm C of this study is closed to accrual for the general patient population, but will remain open to minority accrual only. Arms A and D will remain open to the general patient population, per study design. Research blood draws provided.
|
|
Eligibility:
|
Diagnosis of cancer, Planning to receive paclitaxel (excluding paclitaxel albumin-stabilized nanoparticle formulation [nab-paclitaxel]) according to one of the following dosing schedules: At least 175 mg/m2 at 2-4 week intervals (course duration of 2, 3, or 4 weeks, respectively), 70-90 mg/m2 weekly (3 out of 4 weeks allowed). Prior/Concurrent Therapy: See Disease Characteristics. No prior paclitaxel or neurotoxic chemotherapy drugs, including other taxanes, platinum agents, vinca alkaloids, or epothilones. No concurrent neutrophil colony-stimulating factor therapy. Patient Characteristics: ECOG performance status 0-1, Life expectancy > 6 months, Able to complete questionnaires (alone or with assistance), willing to provide required biological specimens, No prior or concurrent peripheral neuropathy (from diabetes or other causes), No prior or concurrent fibromyalgia.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|